AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...
Check with your school authorities and teachers before using this holiday list. Some holidays may not apply to all areas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback